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Abstract
Introduction—Gastroesophageal reflux disease (GERD) is a common condition that impacts
patients’ health-related quality of life (HRQoL). The HRQoL of Barrett’s esophagus (BE) has
been less well studied. Furthermore, it is unknown to what extent BE patients suffer from
psychological distress as a result of carrying a diagnosis of a premalignant condition. We sought
to compare BE and GERD (stratified by erosive (ERD) and non-erosive reflux disease (NERD))
with regards to HRQoL and psychological impact.
Methods—In this single-center study of subjects presenting for elective upper endoscopy,
consecutive patients with BE and GERD were enrolled. Participants completed questionnaires
assessing generic HRQoL (Medical Outcomes Study Short Form-36: SF-36), disease-specific
HRQoL (Gastrointestinal Quality of Life Index: GIQLI), a measure of psychological distress (the
Revised Hopkins Symptom Checklist: SCL-90R) and a patient-centered assessment of impact of
disease severity (the GERD health-related quality of life measure: GERD HRQL).
Results—Patients with BE had the lowest symptom severity compared to those with NERD or
ERD (GERD HRQL: 13.7 vs. 18 and 15.9 respectively, p<0.01). Those with BE also had better
disease-specific quality of life compared to NERD or ERD patients (GIQLI: 137.2 vs. 124.3 and
131.0 respectively, p<0.001). After adjusting for potential confounding variables including
symptom severity and gender, BE patients continued to demonstrate better disease-specific
HRQoL, scoring 12.2 points higher on the GIQLI than NERD patients (95% CI 5.1 – 19.3) and
16.3 points higher than ERD patients (95% CI 5.4 – 27.3), as well as better generic HRQoL,
scoring 4.8 points higher on the SF-36 physical component summary than NERD patients (95% CI
0.8 – 8.8) and 7.1 points higher than ERD patients (95% CI 1.2–13.1). There were no significant
differences between groups in psychological distress, as demonstrated by the SCL-90R global
severity index, though BE patients scored lower on the somatization domain compared to NERD
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and ERD patients. When stratified by gender, females with NERD and BE had worse disease-
specific HRQoL than males.
Conclusions—Patients with BE have better generic and disease-specific HRQoL when
compared to patients with NERD and ERD. This difference is only partially attributable to lower
symptom severity amongst BE patients. Psychological distress did not differ significantly amongst
groups. Female gender was associated with worsened HRQoL regardless of GERD disease
manifestation. Though more precise instruments may aid in detecting any HRQoL decrements in
BE patients due to perceived cancer risk or fear of developing or dying from cancer, we were
unable to demonstrate an additional decrement in HRQoL due to cancer risk in subjects with BE.
Keywords
Barrett esophagus; Gastroesophageal reflux; Erosive esophagitis; Non-erosive esophagitis; Quality
of Life; Gender
INTRODUCTION
Gastroesophageal reflux disease (GERD) is a common chronic disease, affecting 10–20% of
the American population on a regular basis (1). Symptoms associated with GERD include
heartburn, acid regurgitation, and chest pain as well as “extra-esophageal” manifestations
such as chest pain, nausea, chronic cough, asthma and hoarseness. All of these symptoms
may compromise health-related quality of life (HRQoL). In addition, sleep disturbance and
associated daytime sleepiness, decrease in mealtime enjoyment, and increased medication
costs may contribute to the burden of disease.
Barrett’s esophagus (BE) is a metaplastic change associated with GERD in which the
normal squamous esophageal epithelium transforms into intestinal cells after chronic acidic
insult from reflux. Population studies demonstrate a prevalence of BE between 1–2% (2,3),
but in patients with GERD symptoms, the prevalence of BE ranges from 10 – 18% (2,4).
Barrett’s esophagus is associated with a 30–125-fold increased risk of adenocarcinoma
compared to the general population (5,6). While the relative risk of adenocarcinoma in
patients with BE is quite high, their absolute risk remains low, approximately 0.5% per
patient per year (5). Furthermore, cohort studies have generally not shown a decreased life-
expectancy in BE (7,8). Nonetheless, patients with BE may overestimate their individual
cancer risk (9), which could affect HRQoL and lead to deleterious psychological effects.
The negative impact of GERD alone on HRQoL and daily function has been examined in
numerous studies (10–12). A smaller number of studies have investigated HRQoL in BE
patients, documenting a similar decrement to that seen in GERD patients (13,14).
Theoretically, persons with GERD and BE are at risk for both the HRQoL decrease
attributable to reflux symptoms (i.e. that seen in GERD), as well the psychological burden of
carrying the diagnosis of a pre-cancerous lesion. However, it is unknown to what extent
GERD symptoms are responsible for the decreased HRQoL observed in BE, as opposed to
the contribution of the threat of cancer. Moreover, there are two different manifestations of
GERD: erosive reflux disease (ERD) and non-erosive reflux disease (NERD) (15). Although
their histological manifestation is less severe, NERD patients have been demonstrated to
have severe impairment in HRQoL (16). Non-erosive patients may have a psychological
profile similar to patients with functional bowel disease, who often have increased
psychological distress (17).
We performed a cross-sectional analysis of data from a case-control study of BE and GERD
patients to examine whether patients with BE have different HRQoL than patients with ERD
and NERD, after controlling for patient perception of GERD symptom severity. The aims of
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this study were to isolate any decrease in HRQoL associated with Barrett’s esophagus by
comparing BE patients to GERD patients with similar GERD symptom severity, and to
measure any additional psychological distress that may be associated with BE, which could
potentially be attributed to cancer risk. Additionally, we sought do determine whether any
differences were present in quality of life based on gender and presence of erosive disease.
METHODS
Study Subjects
The original study population was recruited over a 4-year period (2002–2006) from
consecutive patients aged 18–80 presenting for elective upper endoscopy at the
Gastroenterology Endoscopy Clinic at the University of North Carolina with a primary or
secondary indication of reflux symptoms. Cases had both endoscopically and histologically
confirmed prevalent BE. All potential cases were solicited for enrollment. Controls were
patients without BE but with classic GERD symptoms, consisting of substernal chest
burning, regurgitation and/or waterbrash syndrome, with a physician diagnosis of GERD.
The control group was stratified based on the presence or absence of erosive disease as
verified by esophagitis or erosions visualized on same-day endoscopy. Because GERD
patients outnumber BE patients by an estimated 9:1 ratio (4), one fourth of eligible controls
were randomly selected using a computer algorithm. An approximately 1:2 case to control
ratio was used to improve study power.
Patients were excluded if they could not read or comprehend the informed consent or
questionnaires or did not speak English, had undergone prior partial or complete esophageal
resection, had undergone endoscopic ablation of their BE, or were found to have esophageal
carcinoma on the index endoscopy. The research protocol was reviewed and approved by
the Institutional Review Board of the University of North Carolina.
Study Measures
Medical Outcomes Study Short Form-36 (SF-36)—The SF-36 measures generic
HRQoL, which allows comparisons between different disease states. The SF-36 measures
health status in eight domains: physical functioning (PF), role limitations-physical (RP),
bodily pain (BP), general health (GH), vitality (VT), social functioning (SF), role
limitations-emotional (RE), and mental health (MH). Summary physical component (PCS)
and mental component scores (MCS) are also calculated from patient responses (18).
Scores on the SF-36 range from 0–100 on each dimension and on the summary scales, with
higher scores indicating better quality of life. The score is standardized in the general
population with a mean of 50 and a standard deviation of 10. The scale reliability ranges
from 0.78 to 0.93(18). The SF-36 takes relatively little time to complete and has been
validated across many populations. Data are available on patients with a wide range of
conditions such as angina, clinical depression, congestive heart failure, diabetes and
hypertension (19). A 3-point difference on the summary scores is considered clinically
meaningful in GERD (12).
Gastrointestinal Quality of Life Index (GIQLI)—The GIQLI is a system-specific
measure that has been used in multiple gastrointestinal disease states including GERD (20).
It assesses HRQoL in 4 domains: physical well-being, gastrointestinal symptoms, social
well-being, and emotional well-being. The GIQLI is composed of 36 multiple-choice
questions graded on a 0–4 scale; the final score is the sum of the question responses. Higher
scores indicate less severe symptoms and improved HRQoL, and the maximum score is 144.
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The Revised Hopkins Symptom Checklist 90 (SCL-90-R)—The SCL-90-R is a
widely used measure of psychological distress. This instrument contains 90 questions
addressing 9 dimensions of symptoms: somatization (SOM), obsessive-compulsive (OC),
interpersonal sensitivity (IS), depression (DEP), anxiety (ANX), hostility (HOS), phobic
anxiety (PHOB), paranoid ideation (PAR) and psychosis (PSY) (21). There are also 3
summary measures including a global severity index (GSI), a positive symptom distress
index (PSDI) and a positive symptom total (PST). The questions are multiple-choice and
graded on a 0–4 scale, with higher scores indicating more distress.
On each scale of the SCL-90-R, results are expressed as t scores with a population mean of
50 and a standard deviation of 10. General population norms are available for comparison
with study population scores. A t score at or above the 90th percentile indicates a high level
of general psychological distress (22). The SCL-90-R has previously been used to examine
psychological distress in GERD patients but not in BE patients.
The Gastroesophageal Reflux Disease-Health Related Quality of Life
Questionnaire (GERD-HRQL)—The GERD-HRQL was designed to measure patient
perception of severity of symptoms of GERD. It is a 10-question instrument that examines
the intensity and frequency of heartburn, difficulty swallowing, bloating, and the burden of
GERD medication. Answers are graded from 1–5, with a maximum total score of 50 (23).
Higher scores correspond to more severe symptoms and worsened HRQoL. The GERD-
HRQL has been found to be reliable and valid in a wide range of patient groups. We used
this measure to control for patient-centered assessment of GERD symptom severity in our
analysis.
Study Outcomes
The primary outcomes of this study were quality of life and psychological distress, as
measured with a generic quality of life instrument (SF-36), a disease-specific instrument
(GIQLI), and a measure of psychological symptoms (SCL-90-R). We used the 10-item
measure of GERD symptom severity, the GERD-HRQL, to control for the effect of GERD
symptomatology on HRQoL. Results were stratified by disease manifestation (BE vs. NERD
vs. ERD).
Statistical Analysis
This study was designed with >90% power to calculate a 10% difference in SF-36 summary
scores with an alpha of 0.01.
Univariate statistics were used to examine means, standard deviations and shapes of
distributions for continuous variables and frequencies for categorical variables. Missing or
extreme values were identified and corrected as necessary; no data were imputed. Study
participant test scores were eliminated if all questions on a test were answered with the same
answer choice. For bivariate analysis, outcome measures were examined using t-tests for
variables with two categories and one-way ANOVA for variables with more than two
categories.
Multiple linear regression was used to determine the relationship between GERD
manifestation and HRQoL outcomes while controlling for potential confounding factors
(age, gender, race, BMI, current alcohol use, current smoking, current use of an antireflux
medication, comorbidity, and prior mental health diagnosis) and patient perception of GERD
severity. Subjects with missing data on relevant variables were excluded from the
multivariable analyses. Because gender has previously been associated with differences in
quality of life (24), our analysis was repeated after stratification by gender.
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A total of 529 patients met entry criteria and were enrolled in the study. The characteristics
of the study population are shown in Table 1. Patients with BE were older, more commonly
male and Caucasian, and more likely to have had anti-reflux surgery as compared to the
GERD patients. The non-erosive patients were more likely to be female as compared to the
ERD and BE patients (64% female vs. 42% female and 33% female, respectively). Alcohol
and tobacco use were most common in the ERD group. There was little difference between
groups with respect to body mass index, current pharmacologic treatment of GERD (e.g.
with proton pump inhibitor or H2 blocker medication), comorbidities, or prior mental health
diagnosis.
Outcome measures
Response rates—The GERD HRQL questionnaire was completed by 395/529
participants (74.7%), the SF-36 was completed by 374/529 (70.7%), the GIQLI was
completed by 365/529 (69.0%), and the SCL-90R was completed by 391/529 (73.9%).
Response rates did not differ between cases and controls.
Generic quality of life—Unadjusted results of the SF-36 summary scores stratified by
disease manifestation are shown in Table 2. There was a significant difference between
groups with respect to the mental component score (MCS), with BE patients scoring on
average 3 points higher than NERD or ERD patients (51.7 vs. 48.3 and 48.5 respectively, p=
0.02 for comparison). While there was a slight improvement in the physical component
score (PCS) in BE patients compared to controls, this was not statistically significant
(p=0.46).
Multivariate analysis adjusting for potential confounding variables (including symptom
severity) demonstrated a similar difference between BE patients and GERD patients with
respect to the MCS, but it was no longer statistically significant (Table 3). There was a
significant difference on the PCS in the adjusted model, however, with BE patients
demonstrating a better physical component score than both NERD patients (difference of
4.8, 95% CI 0.8 – 8.8) and ERD patients (difference of 7.1, 95% CI 1.2–13.1).
Comparison of subdomain results of the SF-36 demonstrated significant differences between
groups with respect to the bodily pain, vitality and role limitations-emotional subscales, with
BE patients scoring higher than both NERD and ERD patients indicating better HRQoL in
these categories. Patients with BE had better HRQoL in all other subscales of the SF-36
apart from physical functioning (role limitations-physical, general health, social functioning,
and mental health) but these differences were not statistically significant (Figure 1).
Disease-specific quality of life—Unadjusted results from the GIQLI questionnaire in
the 3 groups are shown in Table 2. There was a significant difference between groups with
BE patients scoring higher on the GIQLI than ERD or NERD patients, indicating better
disease-specific HRQoL (137.2 vs. 131.0 and 124.3 respectively, p <0.001). When adjusted
for potential confounding variables, there remained a difference between the BE and GERD
groups, with BE patients scoring 12.2 points higher on the GIQLI than NERD patients (95%
CI 5.1 – 19.3) and 16.3 points higher than ERD patients (95% CI 5.4 – 27.3)(Table 3).
Psychological distress—We found no difference between groups with respect to the
global severity index (GSI) of the SCL-90R in either the unadjusted comparison (Table 2) or
the adjusted model (Table 3). Scores on the 9 dimensions and 3 summary measures of the
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scale are shown in Table 4. Among the psychological dimensions of the SCL-90R, there was
a small, but significant difference between groups with respect to the somatization
dimension, with BE patients scoring lower than ERD and NERD patients (58.3 vs. 59.7 and
57.4 respectively, p = 0.02). This indicates that BE patients may have less psychological
distress related to somatization compared to GERD patients. However, given the lack of an
overall difference in the GSI, multiple testing issues, and the relative instability of the
dimension scores on the SCL-90R, these data must be viewed cautiously.
Role of symptom severity—Subjects with non-erosive disease were found to report
worse patient assessment of GERD symptom severity than those with ERD or BE as
measured by the GERD HRQL (18.0 vs. 15.9 and 13.7 respectively, p <0.01)(Table 2).
When we controlled for patient perception of symptom severity by adding GERD-HRQL
into the regression model, patients with BE continued to display significantly better disease-
specific quality of life than NERD patients, as measured by the GIQLI (137.7 vs. 125.5,
difference = 12.2, 95% CI = 5.1 – 19.3). In addition, BE patients demonstrated improved
generic HRQoL as measured by the physical component summary measure of the SF-36,
when compared with NERD patients (44.6 vs. 39.8, difference = 4.8, 95% CI = 0.8 – 8.8).
The improved SF-36 summary score for BE patients represents a clinically meaningful
difference, given that it is greater than 3.0. There were no significant differences between
ERD and NERD patients on any of the HRQoL or psychological distress summary
measures, nor were there differences between the BE and NERD patients in terms of
psychological distress (as measured by the SCL-90R GSI) (Table 3).
Role of gender—After stratifying by gender, males with BE reported lower symptom
severity than males with GERD. This trend was similar in females, but it did not reach
statistical significance (Figure 2). Women reported significantly worse GI-specific quality of
life in both the NERD and BE groups as compared to men in these groups (Supplementary
Table, Figure 3). Both men and women with NERD still had worsened GIQLI scores
compared to those of ERD and BE men and women. Men with ERD had higher SF-36 PCS
scores than women with ERD, but otherwise, there were no significant differences between
genders with respect to SF-36 summary scores, or SCL-90R GSI.
DISCUSSION
Our study showed there are differences in HRQoL based upon GERD manifestation.
Patients with BE generally had better HRQoL than those with NERD or ERD. After
adjusting for symptom severity, this difference was statistically-significant as measured by
the GIQLI, and the SF-36 mental component summary. There were few differences between
groups with respect to the SCL-90-R, apart from the finding that BE patients had somewhat
less somatization than other groups.
When stratified by gender, both male and female NERD patients reported worse generic
(SF-36) and disease-specific HRQoL (GIQLI) than ERD and BE patients of the same sex.
Women had worse GI-specific quality of life than men in both the NERD and BE groups,
and worse generic HRQoL in the ERD group. Because there were more women in the
NERD group, it appears that the worsened HRQoL in the NERD group is partially
confounded by gender. However, when we controlled for other variables including gender,
the difference in HRQoL between NERD and ERD or BE patients remained statistically
significant.
Overall, these findings suggest that the HRQoL decrement in BE is related to loss of
function secondary to physical symptoms but not psychological distress. It is possible that
patients with NERD may actually have functional esophageal disease with a prominent
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psychological component. The patients with NERD reported significantly worse HRQoL on
almost all measures examined in this study. These findings can be attributed to perceiving
symptoms as more severe and being more refractory to treatment. Because BE patients
presumably had true acidic insults to their esophagus in the past in order to have undergone
metaplasia, the NERD patients might be expected to have the best HRQoL as their disease
manifestation would be the least severe; on the contrary, these subjects demonstrated the
worst quality of life. Additionally, women in each of the groups were observed to have
worse quality of life than men on most study measures. Improved HRQoL in BE patients
may be due to fewer symptoms, as some authors have described (25). A recent population
study estimated that up to 46% of BE patients may be asymptomatic (26). However, this
observation persisted after we controlled for symptom severity. Therefore, we hypothesize
that the trends reported here are due to a heightened sensitivity and symptom perception of
patients with NERD.
As compared to the general population, patients with GERD and BE in this study report
worse quality of life on every dimension of the SF-36, with scores that are comparable to
patients with diabetes and clinical depression (18). Health related quality of life in BE
patients has been assessed by other investigators. Kulig et. al reported SF-36 summary score
results on 702 German patients with BE, 2660 ERD patients, and 2853 NERD patients (14).
The reported PCS and MCS scores for BE patients were 42.6 and 46.2 respectively, similar
to our findings of 41.8 and 51.7. Interestingly, results for NERD patients were higher for the
PCS (43.5 vs. 40.0) and lower for the MCS (43.9 vs. 48.3) compared to our findings.
Eloubedi et. al conducted a study of 107 patients with BE and 104 with GERD but without
BE using the SF-36 and the Quality of Life in Reflux and Dyspepsia (QOLRAD)
questionnaire (13). A measure of symptom severity was also used, but was not controlled for
in a multivariate regression model comparing groups. The authors reported no significant
differences between groups with respect to either HRQoL measure. Two studies have
reported GIQLI scores on BE patients in the 94–96 range, but both were in the pre-operative
setting prior to Nissen fundoplication. Therefore, patients would be expected to be suffering
more severe symptoms than the average BE patient, which may explain the difference
compared to our GIQLI mean of 137.2. One study that utilized the SCL-90 in GERD
patients reported higher scores on dimensions of somatization, obsessiveness, interpersonal
sensitivity, phobia, psychosis, and the global severity index compared to healthy controls
(27,28). While no studies have been done previously using the SCL-90R in BE patients,
several studies have used the Hospital Anxiety and Depression scale (HADS) to evaluate
psychological symptoms. A study of BE patients in an endoscopic surveillance program
reported that BE patients had higher anxiety scores than the general population, but a second
study demonstrated only minimal depression and anxiety for BE patients on the HADS
(29,30).
Our study has several strengths. We assessed a large number of patients with various
manifestations of GERD. Previously validated tools were used to assess HRQoL and
psychological stress. Importantly, we were able to control for several possible confounders
including a patient assessment of GERD symptom severity, which has not been done in past
investigations. GERD manifestation was assessed with same-day endoscopy, minimizing
misclassification.
Several limitations can also be described. All patients in the study were presenting to a
single tertiary care center and may not reflect the population of GERD patients treated in the
community. Additionally, our study population was primarily white, which reflects the
overall BE population but may limit the generalizability to patients of different races.
Importantly, though the parent study was a case-control design, our study measured HRQoL
and psychological distress at one point in time, so that temporality of HRQoL decrements in
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relationship to the time of diagnosis cannot be firmly established. Also, because we did not
demand cessation of acid-suppressive medication prior to endoscopy, our NERD group was
likely “contaminated” with treated erosive disease. It is important to note however, that if
differential misclassification of ERD subjects into the NERD group occurred, the effect
would tend to minimize, not accentuate, the differences in HRQoL we report between the
NERD and ERD groups. Since pH testing was not a part of this study, the NERD group
could also contain patients with typical GERD symptoms but without actual reflux (e.g.
patients with functional heartburn). Nevertheless, such testing is uncommon for GERD
patients in practice, and this group was representative of the typical NERD patients seen at
our institution, contributing to the external validity of our results.
In addition, there are limitations due to the use of multiple HRQoL measurement tools.
Because each participant was asked to fill out 4 different multi-item questionnaires, we did
have missing data for each measure. Though response rates were similar between cases and
controls, patients who completed the HRQoL assessments may still differ from those who
did not do so. Also, because of the nature of the HRQoL measurements used and the
preponderance of subscales for each measure (17 for the SF-36 and SCL-90R combined),
some statistically significant differences between subscales may be a consequence of
multiple testing. However, consistent trends amongst subscales favoring improved HRQoL
on the SF-36 and less psychological distress SCL-90R for BE patients adds validity to the
individual subscale differences. Furthermore, the finding that NERD patients have the most
somatization is supported by prior studies, assuming that functional heartburn patients are
included in this category (17). Nevertheless, because of multiple testing concerns, our a
priori hypothesis testing focused on the summary measure comparisons, and we performed
pairwise comparisons only if oneway ANOVA testing was significant. Therefore, our main
findings in BE patients of reduced symptom severity, improved disease-specific HRQoL,
and improved generic HRQoL as measured by SF-36 summary measures are minimally
affected by multiple testing.
In summary, our study showed that patients with GERD have worse quality of life than
patients with BE, even after controlling for GERD symptoms. When stratified, females have
worse quality of life than males. In addition, patients with GERD symptoms and NERD
have higher levels of psychological distress. Future studies are indicated to further examine
the psychological component of NERD, and efforts should be directed at improving HRQoL
in this disorder. Additionally, more precise instruments may aid in detecting any HRQoL
decrements in BE patients due to perceived cancer risk or fear of developing or dying from
cancer.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
Financial support: This research was supported, in part, by grants from the National Institutes of Health K23
DK59311-01 (Dr. Shaheen), and T32 DK 07634 (Dr. Crockett).
References
1. Locke GR 3rd, Talley NJ, Fett SL, et al. Prevalence and clinical spectrum of gastroesophageal
reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology. 1997;
112:1448–56. [PubMed: 9136821]
Lippmann et al. Page 8













2. Csendes A, Smok G, Burdiles P, et al. Prevalence of Barrett’s esophagus by endoscopy and
histologic studies: a prospective evaluation of 306 control subjects and 376 patients with symptoms
of gastroesophageal reflux. Dis Esophagus. 2000; 13:5–11. [PubMed: 11005324]
3. Ronkainen J, Aro P, Storskrubb T, et al. Prevalence of Barrett’s esophagus in the general
population: an endoscopic study. Gastroenterology. 2005; 129:1825–31. [PubMed: 16344051]
4. Winters C Jr, Spurling TJ, Chobanian SJ, et al. Barrett’s esophagus. A prevalent, occult
complication of gastroesophageal reflux disease. Gastroenterology. 1987; 92:118–24. [PubMed:
3781178]
5. Drewitz DJ, Sampliner RE, Garewal HS. The incidence of adenocarcinoma in Barrett’s esophagus: a
prospective study of 170 patients followed 4.8 years. Am J Gastroenterol. 1997; 92:212–5.
[PubMed: 9040193]
6. O’Connor JB, Falk GW, Richter JE. The incidence of adenocarcinoma and dysplasia in Barrett’s
esophagus: report on the Cleveland Clinic Barrett’s Esophagus Registry. Am J Gastroenterol. 1999;
94:2037–42. [PubMed: 10445525]
7. Anderson LA, Murray LJ, Murphy SJ, et al. Mortality in Barrett’s oesophagus: results from a
population based study. Gut. 2003; 52:1081–4. [PubMed: 12865262]
8. Eckardt VF, Kanzler G, Bernhard G. Life expectancy and cancer risk in patients with Barrett’s
esophagus: a prospective controlled investigation. Am J Med. 2001; 111:33–7. [PubMed:
11448658]
9. Shaheen NJ, Green B, Medapalli RK, et al. The perception of cancer risk in patients with prevalent
Barrett’s esophagus enrolled in an endoscopic surveillance program. Gastroenterology. 2005;
129:429–36. [PubMed: 16083700]
10. El-Dika S, Guyatt GH, Armstrong D, et al. The impact of illness in patients with moderate to
severe gastro-esophageal reflux disease. BMC Gastroenterol. 2005; 5:23. [PubMed: 16004616]
11. Kaplan-Machlis B, Spiegler GE, Revicki DA. Health-related quality of life in primary care patients
with gastroesophageal reflux disease. Ann Pharmacother. 1999; 33:1032–6. [PubMed: 10534213]
12. Revicki DA, Wood M, Maton PN, et al. The impact of gastroesophageal reflux disease on health-
related quality of life. Am J Med. 1998; 104:252–8. [PubMed: 9552088]
13. Eloubeidi MA, Provenzale D. Health-related quality of life and severity of symptoms in patients
with Barrett’s esophagus and gastroesophageal reflux disease patients without Barrett’s esophagus.
Am J Gastroenterol. 2000; 95:1881–7. [PubMed: 10950030]
14. Kulig M, Leodolter A, Vieth M, et al. Quality of life in relation to symptoms in patients with
gastro-oesophageal reflux disease-- an analysis based on the ProGERD initiative. Aliment
Pharmacol Ther. 2003; 18:767–76. [PubMed: 14535869]
15. Orlando RC. Current understanding of the mechanisms of gastro-oesophageal reflux disease.
Drugs. 2006; 66(Suppl 1):1–5. discussion 29–33. [PubMed: 16869342]
16. Kovacs Z, Kerekgyarto O. Psychological factors, quality of life, and gastrointestinal symptoms in
patients with erosive and non-erosive reflux disorder. Int J Psychiatry Med. 2007; 37:139–50.
[PubMed: 17953232]
17. Shapiro M, Green C, Bautista JM, et al. Functional heartburn patients demonstrate traits of
functional bowel disorder but lack a uniform increase of chemoreceptor sensitivity to acid. Am J
Gastroenterol. 2006; 101:1084–91. [PubMed: 16573776]
18. Ware, J.; Kosinski, M.; Dewey, J. How to Score Version 2 of the SF-36 Health Survey. Lincoln,
RI: QualityMetric Incorporated; 2000.
19. Tarlov AR, Ware JE Jr, Greenfield S, et al. The Medical Outcomes Study. An application of
methods for monitoring the results of medical care. JAMA. 1989; 262:925–30. [PubMed:
2754793]
20. Eypasch E, Williams JI, Wood-Dauphinee S, et al. Gastrointestinal Quality of Life Index:
development, validation and application of a new instrument. Br J Surg. 1995; 82:216–22.
[PubMed: 7749697]
21. Derogatis LR, Rickels K, Rock AF. The SCL-90 and the MMPI: a step in the validation of a new
self-report scale. Br J Psychiatry. 1976; 128:280–9. [PubMed: 1252693]
22. Derogatis, LR. SCL-90-R: Administration, Scoring and Procedure Manual. Baltimore: Clinical
Psychometrics Research; 1983.
Lippmann et al. Page 9













23. Velanovich V. The development of the GERD-HRQL symptom severity instrument. Dis
Esophagus. 2007; 20:130–4. [PubMed: 17439596]
24. Enck P, Dubois D, Marquis P. Quality of life in patients with upper gastrointestinal symptoms:
results from the Domestic/International Gastroenterology Surveillance Study (DIGEST). Scand J
Gastroenterol Suppl. 1999; 231:48–54. [PubMed: 10565623]
25. Madisch A, Miehlke S, Sell S, et al. Patients with Barretts esophagus experience less reflux
complaints. Gastroenterology. 2006; 130:A263–A263.
26. Zagari RM, Fuccio L, Wallander MA, et al. Gastro-oesophageal reflux symptoms, oesophagitis
and Barrett’s oesophagus in the general population: the Loiano-Monghidoro study. Gut. 2008;
57:1354–9. [PubMed: 18424568]
27. Nunez-Rodriguez MH, Miranda Sivelo A. Psychological Factors in Gastroesophageal Reflux
Disease Measured by SCL-90-R Questionnaire. Dig Dis Sci. 2008
28. van der Velden AW, de Wit NJ, Quartero AO, et al. Maintenance treatment for GERD: residual
symptoms are associated with psychological distress. Digestion. 2008; 77:207–13. [PubMed:
18617743]
29. Essink-Bot ML, Kruijshaar ME, Bac DJ, et al. Different perceptions of the burden of upper GI
endoscopy: an empirical study in three patient groups. Qual Life Res. 2007; 16:1309–18.
[PubMed: 17634755]
30. Rosmolen W, Boer K, Van Ianschot J, et al. Fear of cancer recurrence after endoscopic and
surgical treatment for early neoplasia in Barrett’s esophagus. Gastroenterology. 2007; 132:A474–
A475.
Lippmann et al. Page 10














Radar graph of relationship between patients with Barrett’s esophagus, erosive esophagitis,
and non-erosive reflux disease with respect to scores on the Medical Outcomes Study Short-
Form-36 (SF-36) subscale scores. Lower scores (towards center of graph) indicate lower
quality of life. Figure shows that Barrett’s esophagus patients scored better than GERD
patients most subscales of the SF-36. Differences were statistically-significant for the bodily
pain, vitality, and role-emotional subscales.
* p <0.05, calculated with ANOVA
PF = physical functioning, RP = role physical, BP = bodily pain, GH = general health, VT =
vitality, SF = social functioning, RE = role emotional, MH = mental health.
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Symptom severity, as measured by the GERD-HRQL score by disease manifestation and
gender.
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Gastrointestinal disease-specific quality of life (as measured by GIQLI), stratified by disease
manifestation and gender.
*by oneway ANOVA, **by t-test
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Table 1
Characteristics of the study population (n = 529)*
GERD
Barrett’s Esophagus (n = 168) p**
Non-erosive (n = 289) Erosive (n = 72)
Age (mean years ± SD) 49.6 ± 13.5 50.3 ± 14.7 57.6 ± 11.5 < 0.001
 Unknown (n) 0 0 1
Gender
 Male (n, %) 105 (36) 42 (58) 112 (67) < 0.001
 Female (n, %) 184 (64) 30 (42) 56 (33)
 Unknown (n) 0 0 0
Race
 White (n, %) 242 (84) 63 (87) 159 (95) <0.01
 Non-white (n, %) 47 (16) 9 (13) 9 (5)
 Unknown (n) 0 0 0
BMI (mean kg/m2 ± SD) 28.8 ± 6.9 27.8 ± 5.2 28.6 ± 5.5 0.5
 Unknown (n) 24 15 8
Current alcohol use
 Yes (n, %) 122 (51) 33 (70) 56 (48) 0.03
 No (n, %) 119 (49) 14 (30) 60 (52)
 Unknown (n) 48 25 52
Current smoking
 Yes (n, %) 39 (16) 12 (27) 25 (20) 0.2
 No (n, %) 199 (84) 33 (74) 100 (80)
 Unknown (n) 51 27 43
Current medical GERD treatment
 Yes (n, %) 251 (94) 59 (95) 152 (94) 0.9
 No (n, %) 16 (6) 3 (5) 10 (6)
 Unknown (n) 22 10 6
Previous GERD surgery
 Yes (n, %) 18 (10) 4 (10) 21 (21) 0.02
 No (n, %) 166 (90) 38 (90) 79 (79)
 Unknown (n) 105 30 68
Comorbid conditions present
 Yes (n, %) 227 (85) 47 (76) 132 (81) 0.20
 No (n, %) 40 (15) 15 (24) 30 (19)
 Unknown (n) 22 10 6
Prior mental health diagnosis
 Yes (n, %) 121 (45) 22 (35) 72 (44) 0.4
 No (n, %) 146 (55) 40 (65) 90 (56)
 Unknown (n) 22 10 6
*
Current alcohol defined as any current alcohol use. Current smoking defined as any current cigarette use. Erosive esophagitis defined as erosive
disease seen on endoscopy. Medical GERD treatment defined as pharmaceutical treatment for GERD symptoms. GERD surgery defined as













Lippmann et al. Page 15
previous surgery for GERD symptoms. Comorbidity defined as any additional non-psychiatric chronic medical condition. Mental health diagnosis
defined as any current or past psychiatric diagnosis.
**
p<0.05 by ANOVA for continuous variables and chi-square for categorical variables; missing data was not included in the statistical analysis.
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Table 2
Overall relationship between quality of life and psychological distress by disease manifestation
Measure (mean ± SD)
GERD
Barrett’s Esophagus (n = 168) p*
Non-erosive (n = 289) Erosive (n = 72)
GERD-HRQL † 18.0 ± 11.2 15.9 ± 10.8 13.7 ± 10.5 < 0.01
 Unknown (n) 72 17 45
SF-36 PCS# 40.0 ± 12.7 40.1 ± 12.5 41.8 ± 12.7 0.5
 Unknown (n) 94 12 49
SF-36 MCS** 48.3 ± 11.0 48.5 ± 11.7 51.7 ± 10.9 0.02
 Unknown (n) 94 12 49
GIQLI‡ 124.3 ± 24.1 131.0 ± 20.8 137.2 ± 21.1 < 0.001
 Unknown (n) 97 15 52
SCL-90-R GSI†† 58.0 ± 11.4 58.0 ± 12.2 56.4 ± 11.7 0.5
 Unknown (n) 84 12 42
*
p value calculated with ANOVA
†
GERD severity based upon 10-question GERD-HRQL. Higher scores indicate more severe symptomatology
#
SF-36 PCS = Physical component summary score from the Medical Outcomes Study Short-Form 36. Lower scores indicate lower quality of life.
**
SF-36 MCS = Mental component summary score from the Medical Outcomes Study Short-Form 36. Lower scores indicate lower quality of life.
‡
GIQLI = Gastrointestinal Quality of Life Index. Lower scores indicate more severe symptoms.
††
SCL-90-R GSI = Global severity index (standardized T-score) of the Revised Hopkins Symptoms Checklist 90. A T score at or above the 90th
percentile indicates a high level of psychological distress.
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Table 4
Relationship between psychologic distress (SCL-90-R) and manifestation of reflux disease
Score* (mean ± SD)
GERD
Barrett’s (n = 168)Non-erosive (n = 289) Erosive (n = 72)
Global severity index 58.0 ± 11.4 58.0 ± 12.2 56.4 ± 11.7
 Somatization† 61.9 ± 11.3 59.7 ± 12.3 58.3 ± 11.6
 Obsessive-compulsive 57.4 ± 11.9 57.9 ± 10.7 56.4 ± 11.7
 Interpersonal sensitivity 54.5 ± 11.4 54.8 ± 12.0 53.0 ± 10.9
 Depression 57.5 ± 11.1 57.2 ± 12.0 57.1 ± 12.2
 Anxiety 55.2 ± 11.6 53.3 ± 11.6 53.2 ± 12.8
 Hostility 53.2 ± 10.3 53.8 ± 10.8 52.7 ± 10.2
 Phobic anxiety 51.9 ± 10.7 51.6 ± 9.3 51.7 ± 9.9
 Paranoid ideation 50.8 ± 11.2 52.5 ± 11.2 50.6 ± 11.3
 Psychoticism 55.9 ± 11.0 56.4 ± 10.2 54.7 ± 10.7
Positive symptom distress index 57.2 ± 9.9 56.9 ± 9.7 55.1 ± 10.4
Positive symptom total 56.8 ± 11.2 56.6 ± 12.0 55.2 ± 10.5
Missing (n) 84 12 42
*
Standardized T scores of the SCL-90-R (Revised Hopkins Symptoms Checklist 90). A T score at or above the 90th percentile indicates a high
level of psychological distress.
†
p = 0.02 for the comparison of the overall score between non-erosive, erosive, and BE subjects. All other comparisons are not significant.
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